Three days ago, I concluded the last published article commenting about the real challenge for parents and advocacy groups in the near future which is about how to provide access to the forthcoming therapies to all children that will be able to benefit from using them. As achondroplasia is not a common condition, the potential market for a drug, or drugs directed to correct the bone growth impairment is limited. As a consequence, these potential therapies tend to be highly expensive.
Well, the topic is pertinent and an actual concern about rare conditions. Not coincidentally, this is also the concern of others. I invite you to read this article just published by the news agency Reuters, about it.